Works matching DE "KINASE inhibitors"
Results: 3198
Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response.
- Published in:
- Molecular Systems Biology, 2025, v. 21, n. 3, p. 231, doi. 10.1038/s44320-025-00085-6
- By:
- Publication type:
- Article
Rare Case of Pediatric Lower Limb Verrucous Venous Malformation: Treatment Approach and Considerations.
- Published in:
- 2025
- By:
- Publication type:
- Case Study
Comparative Efficacy and Safety of JAK Inhibitors in the Management of Rheumatoid Arthritis: A Network Meta-Analysis.
- Published in:
- Pharmaceuticals (14248247), 2025, v. 18, n. 2, p. 178, doi. 10.3390/ph18020178
- By:
- Publication type:
- Article
Integrating MAPK pathway inhibition into standard-of-care therapy for pediatric low-grade glioma.
- Published in:
- Frontiers in Oncology, 2025, p. 1, doi. 10.3389/fonc.2025.1520316
- By:
- Publication type:
- Article
Investigation of thyroid function in dogs treated with the tyrosine kinase inhibitor toceranib.
- Published in:
- Veterinary & Comparative Oncology, 2020, v. 18, n. 3, p. 433, doi. 10.1111/vco.12538
- By:
- Publication type:
- Article
The radiosensitizing effect of the aurora kinase inhibitors, ENMD-2076, on canine mast cell tumours in vitro.
- Published in:
- Veterinary & Comparative Oncology, 2016, v. 14, n. 1, p. 13, doi. 10.1111/vco.12046
- By:
- Publication type:
- Article
Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors.
- Published in:
- Veterinary & Comparative Oncology, 2015, v. 13, n. 1, p. 48, doi. 10.1111/vco.12018
- By:
- Publication type:
- Article
Elevated serum thymidine kinase activity in canine splenic hemangiosarcoma<sup>*</sup> Elevated serum thymidine kinase activity in canine splenic hemangiosarcoma.
- Published in:
- Veterinary & Comparative Oncology, 2012, v. 10, n. 4, p. 292, doi. 10.1111/j.1476-5829.2011.00298.x
- By:
- Publication type:
- Article
A Phosphoramidate Prodrug Platform: One‐Pot Amine Functionalization of Kinase Inhibitors with Oligoethylene Glycol for Improved Water‐Solubility.
- Published in:
- Chemistry - A European Journal, 2024, v. 30, n. 49, p. 1, doi. 10.1002/chem.202401781
- By:
- Publication type:
- Article
Cover Feature: Optimization of the Lead Compound NVP‐BHG712 as a Colorectal Cancer Inhibitor (Chem. Eur. J. 23/2023).
- Published in:
- Chemistry - A European Journal, 2023, v. 29, n. 23, p. 1, doi. 10.1002/chem.202300918
- By:
- Publication type:
- Article
Discovery of Selective and Potent ATR Degrader for Exploration its Kinase‐Independent Functions in Acute Myeloid Leukemia Cells.
- Published in:
- Angewandte Chemie, 2024, v. 136, n. 17, p. 1, doi. 10.1002/ange.202318568
- By:
- Publication type:
- Article
Global Reactivity Profiling of the Catalytic Lysine in Human Kinome for Covalent Inhibitor Development.
- Published in:
- Angewandte Chemie, 2024, v. 136, n. 12, p. 1, doi. 10.1002/ange.202316394
- By:
- Publication type:
- Article
Charting the Chemical Reaction Space around a Multicomponent Combination: Controlled Access to a Diverse Set of Biologically Relevant Scaffolds.
- Published in:
- Angewandte Chemie, 2023, v. 135, n. 41, p. 1, doi. 10.1002/ange.202303889
- By:
- Publication type:
- Article
Discovery of Potent and Exquisitely Selective Inhibitors of Kinase CK1 with Tunable Isoform Selectivity.
- Published in:
- Angewandte Chemie, 2023, v. 135, n. 11, p. 1, doi. 10.1002/ange.202217532
- By:
- Publication type:
- Article
Synergy and Antagonism between Allosteric and Active‐Site Inhibitors of Abl Tyrosine Kinase.
- Published in:
- Angewandte Chemie, 2021, v. 133, n. 37, p. 20358, doi. 10.1002/ange.202105351
- By:
- Publication type:
- Article
Controlling the Covalent Reactivity of a Kinase Inhibitor with Light.
- Published in:
- Angewandte Chemie, 2021, v. 133, n. 37, p. 20340, doi. 10.1002/ange.202103767
- By:
- Publication type:
- Article
From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein‐Templated Synthesis.
- Published in:
- Angewandte Chemie, 2021, v. 133, n. 35, p. 19493, doi. 10.1002/ange.202106295
- By:
- Publication type:
- Article
A Potent and Selective Janus Kinase Inhibitor with a Chiral 3D‐Shaped Triquinazine Ring System from Chemical Space.
- Published in:
- Angewandte Chemie, 2021, v. 133, n. 4, p. 2102, doi. 10.1002/ange.202012049
- By:
- Publication type:
- Article
A Fluorescent Kinase Inhibitor that Exhibits Diagnostic Changes in Emission upon Binding.
- Published in:
- Angewandte Chemie, 2019, v. 131, n. 42, p. 15142, doi. 10.1002/ange.201909536
- By:
- Publication type:
- Article
Stereoelectronic Effects in Ligand Design: Enantioselective Rhodium‐Catalyzed Hydrogenation of Aliphatic Cyclic Tetrasubstituted Enamides and Concise Synthesis of (R)‐Tofacitinib.
- Published in:
- Angewandte Chemie, 2019, v. 131, n. 38, p. 13707, doi. 10.1002/ange.201908089
- By:
- Publication type:
- Article
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
- Published in:
- Angewandte Chemie, 2019, v. 131, n. 15, p. 193, doi. 10.1111/bjh.15440
- By:
- Publication type:
- Article
STEFs: Activated Vinylogous Protein‐Reactive Electrophiles.
- Published in:
- Angewandte Chemie, 2019, v. 131, n. 11, p. 3571, doi. 10.1002/ange.201814073
- By:
- Publication type:
- Article
Furo[3,2‐b]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway.
- Published in:
- Angewandte Chemie, 2019, v. 131, n. 4, p. 1074, doi. 10.1002/ange.201810312
- By:
- Publication type:
- Article
Inhibition of human UDP‐glucuronosyltransferase enzymes by midostaurin and ruxolitinib: implications for drug–drug interactions.
- Published in:
- Biopharmaceutics & Drug Disposition, 2020, v. 41, n. 6, p. 231, doi. 10.1002/bdd.2241
- By:
- Publication type:
- Article
Absorption, tissue disposition, and excretion of fasudil hydrochloride, a RHO kinase inhibitor, in rats and dogs.
- Published in:
- Biopharmaceutics & Drug Disposition, 2020, v. 41, n. 4/5, p. 206, doi. 10.1002/bdd.2231
- By:
- Publication type:
- Article
Real-world study comparing the efficacy of Janus kinase inhibitors in patients with difficult-to-treat rheumatoid arthritis.
- Published in:
- Clinical Rheumatology, 2024, v. 43, n. 11, p. 3285, doi. 10.1007/s10067-024-07117-w
- By:
- Publication type:
- Article
Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study.
- Published in:
- Clinical Rheumatology, 2024, v. 43, n. 8, p. 2503, doi. 10.1007/s10067-024-07041-z
- By:
- Publication type:
- Article
ToRaRI (Tofacitinib in Rheumatoid Arthritis a Real-Life experience in Italy): Effectiveness, safety profile of tofacitinib and concordance between patient-reported outcomes and physician's global assessment of disease activity in a retrospective study in Central-Italy
- Published in:
- Clinical Rheumatology, 2024, v. 43, n. 2, p. 657, doi. 10.1007/s10067-023-06836-w
- By:
- Publication type:
- Article
Rheumatoid arthritis with pulmonary accelerated rheumatoid nodules treated by baricitinib: a case-based review.
- Published in:
- Clinical Rheumatology, 2024, v. 43, n. 2, p. 775, doi. 10.1007/s10067-023-06773-8
- By:
- Publication type:
- Article
Does baricitinib reduce disease activity in patients with systemic lupus erythematosus? A systematic review and meta-analysis of randomized controlled trials.
- Published in:
- Clinical Rheumatology, 2024, v. 43, n. 2, p. 579, doi. 10.1007/s10067-023-06731-4
- By:
- Publication type:
- Article
Potential alleviation of bone mineral density loss with Janus kinase inhibitors in rheumatoid arthritis.
- Published in:
- Clinical Rheumatology, 2024, v. 43, n. 1, p. 117, doi. 10.1007/s10067-023-06735-0
- By:
- Publication type:
- Article
Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.
- Published in:
- Clinical Rheumatology, 2023, v. 42, n. 12, p. 3225, doi. 10.1007/s10067-023-06787-2
- By:
- Publication type:
- Article
Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
- Published in:
- Clinical Rheumatology, 2023, v. 42, n. 6, p. 1593, doi. 10.1007/s10067-023-06529-4
- By:
- Publication type:
- Article
Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box.
- Published in:
- Clinical Rheumatology, 2023, v. 42, n. 2, p. 621, doi. 10.1007/s10067-022-06415-5
- By:
- Publication type:
- Article
Safety of JAK inhibitor use in patients with rheumatoid arthritis who developed herpes zoster after receiving JAK inhibitors.
- Published in:
- Clinical Rheumatology, 2022, v. 41, n. 6, p. 1659, doi. 10.1007/s10067-022-06096-0
- By:
- Publication type:
- Article
Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
- Published in:
- Clinical Rheumatology, 2022, v. 41, n. 2, p. 499, doi. 10.1007/s10067-021-05894-2
- By:
- Publication type:
- Article
A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis.
- Published in:
- Clinical Rheumatology, 2022, v. 41, n. 1, p. 33, doi. 10.1007/s10067-021-05973-4
- By:
- Publication type:
- Article
Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis.
- Published in:
- Clinical Rheumatology, 2021, v. 40, n. 11, p. 4369, doi. 10.1007/s10067-021-05933-y
- By:
- Publication type:
- Article
Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
- Published in:
- Clinical Rheumatology, 2021, v. 40, n. 11, p. 4457, doi. 10.1007/s10067-021-05911-4
- By:
- Publication type:
- Article
Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials.
- Published in:
- Clinical Rheumatology, 2021, v. 40, n. 11, p. 4671, doi. 10.1007/s10067-021-05884-4
- By:
- Publication type:
- Article
Comparison of the effects of baricitinib and tocilizumab on disease activity in patients with rheumatoid arthritis: a propensity score matching analysis.
- Published in:
- Clinical Rheumatology, 2021, v. 40, n. 8, p. 3143, doi. 10.1007/s10067-021-05815-3
- By:
- Publication type:
- Article
Performance of Janus kinase inhibitors in psoriatic arthritis with axial involvement in indirect comparison with ankylosing spondylitis: a retrospective analysis from pooled data.
- Published in:
- Clinical Rheumatology, 2021, v. 40, n. 5, p. 1725, doi. 10.1007/s10067-020-05442-4
- By:
- Publication type:
- Article
Hypereosinophilic syndrome—a rare adverse event of anti-cytokine treatment in rheumatoid arthritis resolved after Janus kinase inhibitor therapy.
- Published in:
- Clinical Rheumatology, 2020, v. 39, n. 11, p. 3507, doi. 10.1007/s10067-020-05134-z
- By:
- Publication type:
- Article
Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials.
- Published in:
- Clinical Rheumatology, 2019, v. 38, n. 2, p. 523, doi. 10.1007/s10067-018-4299-4
- By:
- Publication type:
- Article
A liquid biopsy in primary lung cancer.
- Published in:
- Surgery Today, 2019, v. 49, n. 1, p. 1, doi. 10.1007/s00595-018-1659-2
- By:
- Publication type:
- Article
Weight gain secondary to the use of Janus kinase inhibitors.
- Published in:
- Archives of Dermatological Research, 2023, v. 315, n. 10, p. 2773, doi. 10.1007/s00403-023-02710-6
- By:
- Publication type:
- Article
Molecular Docking and 3D QSAR Research of Indolocarbazole Series as Cyclin-Dependent Kinase Inhibitors.
- Published in:
- Journal of Structural Chemistry, 2018, v. 59, n. 7, p. 1555, doi. 10.1134/S0022476618070065
- By:
- Publication type:
- Article
Discovery of anaplastic lymphoma kinase inhibitors from natural product library: A holistic in silico approach.
- Published in:
- Biotechnology & Applied Biochemistry, 2021, v. 68, n. 6, p. 1185, doi. 10.1002/bab.2040
- By:
- Publication type:
- Article
Ensemble Pharmacophore Meets Molecular Docking: A Novel Screening Approach for the Identification of B-Raf Kinase Inhibitors.
- Published in:
- Trends in Sciences, 2023, v. 20, n. 1, p. 1, doi. 10.48048/tis.2023.6403
- By:
- Publication type:
- Article
The Aurora kinase inhibitor AT9283 inhibits Burkitt lymphoma growth by regulating Warburg effect.
- Published in:
- PeerJ, 2023, p. 1, doi. 10.7717/peerj.16581
- By:
- Publication type:
- Article